RSS   Newsletter   Contact   Advertise with us
Post Online Media

InMed appoints Martin Bott to board of directors

InMedInMed Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, announced that Martin Bott, VP of corporate finance and investment banking at Eli Lilly & Company, has been appointed to InMed board of directors.
Article continues below

READ MORE InMed appoints Andrew Hull to board

Mr. Bott brings over 28 years of senior financial and executive leadership to InMed’s Board of Directors.

Mr. Bott joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK.

Prior to his current assignment, he was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.

Mr. Bott has a Bachelors of Business / Marketing (Cologne, Germany, 1985) and a Master’s in International Business Studies (University of South Carolina, 1988).

 LATEST MOVES FROM British Columbia 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy